< Back to the Blog

About the author

Dr Mary Parman
Dr. Mary Parman is an OB/GYN with nearly 20 years of experience and a leading voice at the intersection of clinical care and women’s health technology.

Sources

  1. Baber RJ, Panay N, Fenton A. "2016 IMS Recommendations on women's midlife health and menopause hormone therapy." Climacteric. 2016;19(2):109–150.
  2. Canonico M, Plu-Bureau G, Lowe GD, Scarabin PY. "Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis." BMJ. 2008;336(7655):1227–1231.
  3. Prior JC. "Progesterone for symptomatic perimenopause treatment: Progesterone politics, physiology and potential for perimenopause." Facts Views Vis Obgyn. 2011;3(2):109–120.
  4. Stuenkel CA, Davis SR, Gompel A, et al. "Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline." Journal of Clinical Endocrinology & Metabolism. 2015;100(11):3975–4011.
  5. Backstrom T, Haage D, Lofgren M, et al. "Paradoxical effects of GABA-A modulators may explain sex steroid induced negative mood symptoms in some patients." Neuroscience. 2011;191:46–54.
  6. Scarabin PY, Oger E, Plu-Bureau G. "Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk." Lancet. 2003;362(9382):428–432.
  7. Gordon JL, Rubinow DR, Eisenlohr-Moul TA, et al. "Efficacy of transdermal estradiol and micronized progesterone in the prevention of depressive symptoms in the menopause transition." JAMA Psychiatry. 2018;75(2):149–157.

About the Oova Blog:
Our content is developed with a commitment to high editorial standards and reliability. We prioritize referencing reputable sources and sharing where our insights come from. The Oova Blog is intended for informational purposes only and is never a substitute for professional medical advice. Always consult a healthcare provider before making any health decisions.